Publication details

Growth Phase Matters: Boosting immunity via Lacticasebacillus-derived membrane vesicles and their interactions with TLR2 pathways

Investor logo
Investor logo
Authors

SANDANUSOVÁ Miriam TURKOVA Kristyna PECHÁČKOVÁ Eva KOTOUCEK Jan ROUDNICKÝ Pavel ŠINDELÁŘ Martin KUBALA Lukáš AMBROZOVA Gabriela

Year of publication 2024
Type Article in Periodical
Magazine / Source Journal of Extracellular Biology
MU Faculty or unit

Faculty of Science

Citation
web https://isevjournals.onlinelibrary.wiley.com/doi/10.1002/jex2.169
Doi http://dx.doi.org/10.1002/jex2.169
Keywords growth curve; immunomodulation; Lacticaseibacillus rhamnosus; lipoteichoic acid; membrane vesicles; nanocarriers; TLR2
Attached files
Description Lipid bi-layered particles known as membrane vesicles (MVs), produced by Gram-positive bacteria are a communication tool throughout the entire bacterial growth. However, the MVs characteristics may vary across all stages of maternal culture growth, leading to inconsistencies in MVs research. This, in turn, hinders their employment as nanocarriers, vaccines and other medical applications. In this study, we aimed to comprehensively characterize MVs derived from Lacticaseibacillus rhamnosus CCM7091 isolated at different growth stages: early exponential (6 h, MV6), late exponential (12 h, MV12) and late stationary phase (48 h, MV48). We observed significant differences in protein content between MV6 and MV48 (data are available via ProteomeXchange with identifier PXD041580), likely contributing to their different immunomodulatory capacities. In vitro analysis demonstrated that MV48 uptake rate by epithelial Caco-2 cells is significantly higher and they stimulate an immune response in murine macrophages RAW 264.7 (elevated production of TNF?, IL-6, IL-10, NO). This correlated with increased expression of lipoteichoic acid (LTA) and enhanced TLR2 signalling in MV48, suggesting that LTA contributes to the immunomodulation. In conclusion, we showed that Lacticaseibacillus rhamnosus CCM7091-derived MVs from the late stationary phase boost the immune response the most effectively, which pre-destines them for therapeutical application as nanocarriers.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info